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Abstract.13
Background: Microarray technologies have identified imbalances in the expression of specific genes and biological pathways
in Alzheimer’s disease (AD) brains. However, there is a lack of reproducibility across individual AD studies, and many related




Objective: Meta-analyze publicly available transcriptomic data from multiple brain-related disorders to identify robust
transcriptomic changes specific to AD brains.
17
18
Methods: Twenty-two AD, eight schizophrenia, five bipolar disorder, four Huntington’s disease, two major depressive
disorder, and one Parkinson’s disease dataset totaling 2,667 samples and mapping to four different brain regions (temporal
lobe, frontal lobe, parietal lobe, and cerebellum) were analyzed. Differential expression analysis was performed independently







Results: Meta-analysis identified 323, 435, 1,023, and 828 differentially expressed genes specific to the AD temporal lobe,
frontal lobe, parietal lobe, and cerebellum brain regions, respectively. Seven of these genes were consistently perturbed
across all AD brain regions with SPCS1 gene expression pattern replicating in RNA-Seq data. A further nineteen genes
were perturbed specifically in AD brain regions affected by both plaques and tangles, suggesting possible involvement in
AD neuropathology. In addition, biological pathways involved in the “metabolism of proteins” and viral components were







Conclusion: This study identified transcriptomic changes specific to AD brains, which could make a significant contribution
toward the understanding of AD disease mechanisms and may also provide new therapeutic targets.
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INTRODUCTION 34
Alzheimer’s disease (AD) is the most common 35
form of dementia affecting over 44 million individu- 36
als worldwide, and numbers are expected to triple by 37
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2050 [1]. The hallmark of the disease is characterized38
by the abnormal brain accumulation of amyloid-39
(A) protein and hyperphosphorylated tau filaments,40
which forms structures known as plaques and tan-41
gles, respectively. The accumulation of these proteins42
contributes to the loss of connections between neuron43
synapses, leading to the loss of brain tissue and the44
disruption of normal cognitive functions.45
As AD progresses, the spread of plaques and tan-46
gles in the brain usually occurs in a predictable pattern47
and can begin up to 18 years prior to the onset of clini-48
cal symptoms [2]. In the earliest stages of the disease,49
plaques and tangles form in areas of the brain primar-50
ily involved in learning and memory, specifically the51
hippocampus and entorhinal cortex, both situated in52
the temporal lobe (TL) region [3]. Next, the frontal53
lobe (FL), a region involved in voluntary movement,54
is affected, followed by the parietal lobe (PL), a region55
involved in processing reading and writing. In the56
later stage of the disease, the occipital lobe, a region57
involved in processing information from the eyes, can58
become affected, followed by the cerebellum (CB),59
a region which receives information from the sen-60
sory systems and the spinal cord to regulates motor61
movement. Nerve cell death, tissue loss, and atrophy62
occur throughout the brain as AD progresses, leading63
to the manifestation of clinical symptoms associated64
with loss of normal brain function. However, not all65
brain regions are neuropathologically affected in the66
same manner. The CB, which only accounts for 10%67
of the brain but contains over 50% of the brain’s total68
neurons, is often neglected in AD research because69
it is generally considered to be partially spared from70
the disease as plaques are only occasionally seen but71
tangles are generally not reported [4, 5].72
The histopathological spread of the disease is well73
documented, and with the advent of high throughput74
genomics approaches, we are now able to study the75
transcriptomic and biological pathways disrupted in76
AD brains. Microarrays can simultaneously exam-77
ine thousands of genes, providing an opportunity78
to identify imbalances in the expression of specific79
genes and biological pathways. However, microar-80
ray reproducibility has always been questionable,81
with replication of differentially expressed genes82
(DEGs) very poor [6]. For example, two independent83
microarray transcriptomic studies performed differ-84
ential expression analysis in the hippocampus of AD85
brains. The first study by Miller et al. identified 60086
DEGs [7], and a similar study by Hokama et al. iden-87
tified 1071 DEGs [8]. An overlap of 105 DEGs exist88
between the two studies; however, after accounting89
for multiple testing, no gene was replicated between 90
the two studies. The Miller study consisted of 7 91
AD and 10 control subjects expression profiled on 92
the Affymetrix platform while the Hakoma study 93
consisted of 31 AD and 32 control subjects expres- 94
sion profiled on the Illumina platform. Replication 95
between the Illumina and Affymetrix platform has 96
been shown to be generally very high [9]; therefore, 97
the lack of replication between the two studies is 98
probably down to a range of other factors includ- 99
ing low statistical power, sampling bias, and disease 100
heterogeneity. 101
Unlike DEGs, replication of the molecular changes 102
at a pathway level are more consistent and have 103
provided insights into the biological processes dis- 104
turbed in AD. Numerous studies have consistently 105
highlighted disruptions in immune response [10–13], 106
protein transcription/translation [10, 11, 14–17], cal- 107
cium signaling [10, 18, 19], MAPK signaling [7, 16], 108
various metabolism pathways such as carbohydrates 109
[16], lipids [16, 20], glucose [17, 21, 22], iron [11, 110
23], chemical synapse [7, 18, 19], and neurotransmit- 111
ter [11, 18, 19]. However, many of these pathways 112
have also been suggested to be disrupted in other 113
brain-related disorders. For example, disruptions in 114
calcium signaling, MAPK, chemical synapse, and 115
various neurotransmitter pathways have also been 116
implicated in Parkinson’s disease (PD) [24, 25]. In 117
addition, glucose metabolism, protein translation, 118
and various neurotransmission pathways have also 119
been suggested to be disrupted in bipolar disorder 120
(BD) [26–29]. Although the biological disruptions 121
involved in AD are steadily being identified, many 122
other neurodegenerative and mental disorders are 123
showing similar perturbations. We are yet to identify 124
robust transcriptomic changes specific to AD brains. 125
In this study, we combined publicly available 126
microarray gene expression data generated from AD 127
human brain tissue and matched cognitively healthy 128
controls to conduct the most extensive AD transcrip- 129
tomic microarray meta-analyses known to date. We 130
generate AD expression profiles across the TL, FL, 131
PL, and CB brain regions. We further refine each 132
expression profile by removing perturbations seen in 133
other neurodegenerative and mental disorders (PD, 134
BD, schizophrenia [SCZ], major depressive disorder 135
[MDD], and Huntington’s disease [HD]) to decipher 136
specific transcriptomic changes occurring in human 137
AD brains. These AD-specific brain changes may 138
provide new insight and a better understanding of the 139
disease mechanism, which in turn could provide new 140
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MATERIALS AND METHODS142
Selection of publicly available microarray143
studies144
Publicly available microarray gene expres-145
sion data was sourced from the Accelerating146




2018.185) and ArrayExpress (https://www.ebi.ac.uk/151
arrayexpress/) in June 2016. For a study to be selected152
for inclusion, the data had to 1) be generated from153
a neurodegenerative or mental health disorder,154
2) be sampled from human brain tissue, 3) have155
gene expression measured on either the Affymetrix156
or Illumina microarray platform, 4) contain both157
diseased and suitably matched healthy controls in the158
same experimental batch, and 5) contain at least 10159
samples from both the diseased and control group.160
Microarray gene expression data pre-processing161
Data analysis was performed in RStudio (ver-162
sion 0.99.467) using R (version 3.2.2). All data163
analysis scripts used in this study are available164
at https://doi.org/10.5281/zenodo.823256. In brief,165
raw Affymetrix microarray gene expression data166
was “mas5” background corrected using R package167
“affy” (version 1.42.3) and raw Illumina microarray168
gene expression data Maximum Likelihood Estima-169
tion (MLE) background corrected using R package170
“MBCB” (version 1.18.0). Studies with samples171
extracted from multiple tissues were separated into172
tissue-specific matrices, log2 transformed and then173
Robust Spline Normalised (RSN) using R package174
“lumi” (version 2.16.0).175
BRAAK staging is a measure of AD pathology and176
ranges from I-VI. In general, stages I-II, III-IV and177
V-VI represent the “low likelihood of AD”, “probable178
AD” and “definite AD” respectively [30]. To main-179
tain homogeneity within the sample groups and to be180
able to infer pathological related genetic changes, if181
BRAAK staging was available, clinical AD samples182
with BRAAK scores ≤3 or clinical control samples183
with BRAAK scores ≥3 were removed from further184
analysis.185
Gender was predicted using the R package “mas-186
siR” (version 1.0.1) and used to subset the data into187
four groups based on diagnosis (case/control) and188
gender (male/female). Next, probes below the 90th189
percentile of the log2 expression scale in over 80% 190
of samples were deemed “not reliably detected” and 191
were excluded from further analysis to eliminate 192
noise [31] and increase power [32]. 193
Publicly available data is often accompanied by 194
a lack of sample processing information, making 195
it impossible to adjust for known systematic errors 196
introduced when samples are processed in multiple 197
batches, a term often known as “batch effects”. 198
To account for both known and latent variation, 199
batch effects were estimated and removed using the 200
Principal Component Analysis (PCA) and Surrogate 201
Variable Analysis (SVA) using the R package “sva” 202
(version 3.10.0). Gender and diagnosis information 203
were used as covariates in sva when correcting 204
for batch effects. Outlying samples were itera- 205
tively identified and removed from each gender 206
and diagnosis group using fundamental network 207
concepts described in [33]. Platform-specific probe 208
ID’s were converted to Entrez Gene ID’s using 209
the BeadArray corresponding R annotation files 210
(“hgu133plus2.db”, “hgu133a.db”, “hgu133b.db”, 211
“hugene10sttranscriptcluster.db”, “illuminaHu- 212
manv4.db”, “illuminaHumanv3.db”) and differential 213
expression analysis was performed within each 214
dataset using the R package “limma” (version 215
3.20.9). 216
Finally, study compatibility analysis was investi- 217
gated through the R package “MetaOmics” (version 218
0.1.13). This package uses DEGs, co-expression, and 219
enriched biological pathways analysis to generate 220
six quantified measures that are used to generate 221
a PCA plot. The direction of each quality control 222
(QC) measure is juxtaposed on top of the two- 223
dimensional PC subspace using arrows. Datasets 224
in the negative region of the arrows were classed 225
as outliers [34] and were removed from further 226
analysis. 227
Meta-analysis 228
Datasets were grouped by the primary cerebral cor- 229
tex lobes (TL, FL, PL) and the CB. Meta-analysis 230
was performed using a “combining p-values” method 231
known as “Adaptively Weighted with One-sided 232
Correction” (AW.OC), implemented through the R 233
package “MetaDE” (version 1.0.5) [34]. A com- 234
bining p-value method was chosen to address the 235
biases introduced from different platforms. AW.OC 236
was chosen as it permits missing information across 237
datasets which are introduced by combining data 238
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expression chips. This avoids the need to subset indi-240
vidual datasets to common probes, which essentially241
allows for the maximum number of genes to be ana-242
lyzed. Furthermore, the method provides additional243
information on which dataset is contributing towards244
the meta-analysis p-value, and has been shown to be245
amongst the best performing meta-analysis methods246
for combining p-values for biological associations247
[35]. The meta-analysis method does not provide248
an overall directional change for each gene; there-249
fore, the standard error (SE) was calculated from250
the DE logFC values of each gene across the AW251
assigned significant datasets and used for standard252
meta-summary estimate analysis using the R pack-253
age “rmeta” (version 2.16). This served as the “meta254
expression” change in downstream analysis where255
positive values represent a gene being upregulated256
in AD and negative values as being downregulated in257
AD. Selecting DEGs based on an arbitrary expression258
change significantly influences the interpretation of259
DE results [36]. At least half of differential expres-260
sion based studies incorporate a fold change cut-off261
typically between 2–3; however, informative RNAs262
and expressed transcripts have been shown to have a263
fold change less than 2 [37], and genes with low fold264
change have been demonstrated to influence biologi-265
cal effects in signaling cascades and pathways [36]. In266
addition, gene expression is heavily influenced by tis-267
sue, and as this study performs meta-analysis across268
multiple inter-related tissues within larger brain com-269
partments, we do not employ an arbitrary fold270
change cut-off to determine if a gene is differentially271
expressed; however, we do require the gene to be con-272
sistently expressed across these tissues. If a gene was273
significantly DE according to the meta-analysis (FDR274
adjusted meta p-value ≤0.05), but at least one con-275
tributing dataset (according to AW.OC weights) had276
directional logFC discrepancy (i.e., upregulated in277
one dataset and downregulated in another dataset), the278
gene was deemed to be discordant and was excluded279
from further analysis. This ensured we only captured280
robust, and consistently reproducible expression281
signatures.282
Generation of disease-specific meta-analysis283
expression profiles284
Meta-analysis was performed across all AD285
datasets, followed by a separate meta-analysis286
across the non-AD disorder datasets. Using these287
meta-analysis results we generated three expression288
profiles: 1) “AD expression profile”, 2) “AD-specific289
expression profile”, and 3) “common neurological 290
disorder expression profile”. 291
The first expression profile, “AD expression pro- 292
file”, is a direct result of the meta-analysis performed 293
on AD studies, which represents the changes typi- 294
cally observed from an AD and cognitively healthy 295
control study design. The second expression profile, 296
deemed as the “AD-specific expression profile”, is 297
produced by subtracting significantly DEGs found 298
in the non-AD meta-analysis results from the “AD 299
expression profile”. This profile represents transcrip- 300
tomic changes specifically observed in AD and not 301
in any other neurodegenerative or mental health 302
disorder used in this study. The third expression pro- 303
file, deemed as the “common neurological disorder 304
expression profile”, represents genes which are sig- 305
nificantly DE in all disorders used in this study, 306
including AD. 307
Replication of significant microarray genes in 308
RNA-Seq data 309
The genes significantly DE and deemed to be of 310
biological significance in this study were queried 311
in the curated web-based database Agora (data ver- 312
sion 9, accessible at https://agora.ampadportal.org), 313
which provides expression change of genes in AD 314
based on RNA-Seq of 2100 human brain samples. 315
Functional and gene set enrichment analysis 316
Gene set enrichment analysis (GSEA) and Gene 317
Ontology (GO) analysis was conducted using an 318
Over-Representation Analysis (ORA) implemented 319
through the ConsensusPathDB web platform (version 320
32) [38] in May 2017. ConsensusPathDB incor- 321
porates numerous well-known biological pathway 322
databases including BioCarta, KEGG, Reactome, and 323
Wikipathways. The platform performs a hypergeo- 324
metric test while integrating a background gene list, 325
which in this case is a list of all the genes that pass 326
quality control in this study, compiles results from 327
each database and corrects for multiple testing using 328
the false discovery rate (FDR) [38]. A minimum over- 329
lap of the query signature and database was set to 2, 330
and a result was deemed significant if the q-value was 331
≤0.05. 332
Network analysis 333
Protein-protein interaction (PPI) networks were 334
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lists (referred to as seeds in network analy-336
sis) along with their meta logFC expression337
values to NetworkAnalyst’s web-based platform338
http://www.networkanalyst.ca/faces/home.xhtml in339
June 2017. The “Zero-order Network” option was340
incorporated to allow only seed proteins directly341
interacting with each other, preventing the well-342
known “Hairball effect” and allowing for better343
visualization and interpretation [39]. Sub-modules344
with a p-value ≤0.05 (based on the “InfoMap” algo-345
rithm [40]) were considered significant key hubs, and346
the gene with the most connections within this hub347
was regarded as the key hub gene.348
RESULTS349
The AD microarray datasets350
We Identified and acquired nine publicly avail-351
able AD studies from ArrayExpress and AMP-AD,352
of which seven studies contained samples extracted353
from differing regions of the brain. The basic char-354
acteristics of each study and dataset are provided in355
Table 1. Separating the nine studies by brain regions356
resulted in 46 datasets. Here a “dataset” is defined by357
brain region and study origin. For example, ArrayEx-358
press study E-GEOD-36980 consists of diseased and359
healthy samples extracted from three different tissues360
(temporal cortex, hippocampus, and frontal cortex).361
All samples originating from the same tissue were362
classified as one dataset; therefore, study E-GEOD-363
36980 generated three datasets, representing the three364
different tissues.365
The 46 AD datasets contained both AD samples366
and healthy controls, were assayed using seven dif-367
ferent expression chips over two different microarray368
platforms (Affymetrix and Illumina) and consisted369
of a total 2,718 samples before QC. Briefly, the370
MetaOmics analysis identified study syn4552659 as371
an outlier and was therefore removed from further372
analysis (see the Supplementary Material), result-373
ing in 1,501 samples (746 AD, 755 controls) in the374
remaining 22 datasets after QC.375
Summary of the AD meta-analysis DEG counts376
The AD meta-analysis was performed on the 22377
AD datasets and independently identified differen-378
tially expressed genes within the TL, FL, PL, and379
CB brain regions. A summary of the number of380
datasets in each brain region and the number of sig-381
nificant DEGs identified is provided in Table 2. The382
complete DE results are provided in Supplementary383
Table 1. As mentioned in the methods, due to gene 384
expression being influenced by tissue source and as 385
this study incorporates different brain regions, we do 386
not employ an arbitrary cut-off value to determine 387
genes that are highly or lowly expressed, but primar- 388
ily focus on genes consistently perturbed. However, 389
we provide the meta expression values in the Sup- 390
plementary tables and advise readers to consider 391
the expression distribution of all DEGs within each 392
brain region independently, if determining whether a 393
gene is highly/lowly expressed. For instance, the CB 394
meta expression ranges from –0.53 to 0.54 with an 395
interquartile range (Q1–Q3) of –0.1 to 0.1. In con- 396
trast, the PL has a larger meta expression range of 397
–1.5 to 1.35, with an interquartile range (Q1–Q3) of 398
–0.53 to 0.29. Therefore, as gene expression distribu- 399
tion varies across brain regions, a sensible cut-off (if 400
one was to be used) for highly and lowly expressed 401
genes may lie at the 1st and 3rd quartiles, respectively, 402
with quartiles calculated per tissue. 403
The non-AD disorder microarray datasets 404
Nine non-AD studies were identified and acquired, 405
of which four studies consisted of samples generated 406
from multiple disorders and brain regions. Separat- 407
ing the studies by disease and tissue equated to 21 408
datasets consisting of 8 SCZ, 6 BD, 4 HD, 2 MDD, 409
and 1 PD dataset with a total of 1,166 samples after 410
QC. The demographics of the non-AD datasets is 411
provided in Table 3. 412
Summary of non-AD brain disorder 413
meta-analyses DEG counts 414
A second meta-analysis was performed on all 415
non-AD disorders, and similarly to the AD meta- 416
analysis, datasets were grouped into the TL, FL, PL, 417
and CB brain regions. An overview of the non-AD 418
meta-analysis results are provided in Table 4, and a 419
complete list of DEGs is provided in Supplementary 420
Table 2. SCZ and BD were the only disorders with 421
expression data available across all four brain regions, 422
and the FL brain region was the only region with 423
expression data available from all non-AD disorders 424
identified in this study. 425
The meta-analysis expression profiles 426
As described in the methods, three primary expres- 427
sion signatures were derived from the meta-analyses 428
for each of the four brain regions: 1) “AD expression 429



















Characteristics of individual AD studies processed in this meta-analysis
Data Accession Microarray BeadArray Tissue source (as stated Meta-Analysis Number of samples after QC
repository details platform in the original study brain region
(Publication) publication) mapping
AD (M/F) Control (M/F)
ArrayExpress E-GEOD-118553 Illumina HumanHT-12 v4 Entorhinal Cortex Temporal Lobe 35 (14/21) 21 (12/9)
Cerebellum Cerebellum 38 (10/28) 19 (5/14)
Frontal Cortex Frontal Lobe 38 (13/25) 22 (11/11)





Entorhinal Cortex Temporal Lobe 11 (6/5) 38 (21/17)
Hippocampus Temporal Lobe 15 (8/7) 41 (22/19)
Postcentral Gyrus Parietal Lobe 19 (11/8) 33 (20/13)
Superior Frontal Gyrus Frontal Lobe 17 (8/9) 38 (22/16)
ArrayExpress E-GEOD-29378
([7])
Illumina HumanHT-12 v3 Hippocampus CA1 Temporal Lobe 16 (9/7) 16 (11/5)





Frontal Cortex Frontal Lobe 14 (7/7) 17 (9/8)
Hippocampus Temporal Lobe 7 (3/4) 10 (5/5)















Entorhinal Cortex Temporal Lobe 10 (4/6) 13 (11/2)
Hippocampus CA1 Temporal Lobe 10 (4/6) 13 (10/3)
Medial Temporal Gyrus Temporal Lobe 16 (10/6) 12 (8/4)
Posterior Cingulate Parietal Lobe 9 (4/5) 13 (10/3)





Temporal Cortex Temporal Lobe 189 (93/96) 186 (116/70)






















Frontal Pole Frontal Lobe 25 (6/19) 7 (4/3)
Precentral Gyrus Frontal Lobe 20 (5/15) 3 (1/2)
Inferior Frontal Gyrus Frontal Lobe 19 (5/14) 4 (1/3)
Dorsolateral Prefrontal Cortex Frontal Lobe 19 (4/15) 8 (4/4)
Superior Parietal Lobule Parietal Lobe 11 (2/9) 5 (2/3)
Prefrontal Cortex Frontal Lobe 23 (7/16) 4 (2/2)
Parahippocampal Gyrus Temporal Lobe 18 (5/13) 7 (3/4)
Hippocampus Temporal Lobe 20 (5/15) 5 (2/3)
Inferior Temporal Gyrus Temporal Lobe 20 (5/15) 6 (3/3)
Middle Temporal Gyrus Temporal Lobe 15 (4/11) 7 (4/3)
Superior Temporal Gyrus Temporal Lobe 15 (3/12) 8 (4/4)





Frontal Pole Frontal Lobe 26 (8/18) 7 (4/3)
Precentral Gyrus Frontal Lobe 18 (4/14) 3 (1/2)
Inferior Frontal Gyrus Frontal Lobe 21 (5/16) 5 (2/3)
Dorsolateral Prefrontal Cortex Frontal Lobe 20 (5/15) 8 (4/4)
Superior Parietal Lobule Parietal Lobe 16 (5/11) 5 (3/2)
Prefrontal Cortex Frontal Lobe 23 (7/16) 4 (2/2)
Parahippocampal Gyrus Temporal Lobe 19 (7/12) 7 (3/4)
Hippocampus Temporal Lobe 22 (6/16) 5 (2/3)
Inferior Temporal Gyrus Temporal Lobe 21 (6/15) 7 (4/3)
Middle Temporal Gyrus Temporal Lobe 23 (8/15) 7 (4/3)
Superior Temporal Gyrus Temporal Lobe 23 (4/19) 8 (4/4)
Frontal Pole Frontal Lobe 26 (8/18) 7 (4/3)
Nine publicly available AD studies were identified and acquired for this study. Separating the studies by tissue resulted in 46 datasets, each containing AD and healthy control samples. The brain
tissue in each of the 46 datasets was mapped to their corresponding cerebral cortex (temporal lobe, frontal lobe, or parietal lobe) or the cerebellum. Due to limited phenotypic information in
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Table 2
Summary of AD study meta-analysis DEGs
Brain region Number of Number of AW.OC Significant DEGs
datasets samples (FDR adjusted p≤ 0.05)
(case/control)
Temporal lobe 14 850 (419/431) 323
Frontal lobe 4 180 (92/88) 460
Parietal lobe 2 74 (28/46) 1736
Cerebellum 2 397 (207/190) 867
Twenty-two AD datasets containing a total of 1,501 samples remained in this study after
QC. The case/control numbers represent the total number of AD/healthy controls subjects
across all datasets within a particular brain region. The number of significant genes was
identified through a combining p-value method known as Adaptively Weighted with One-
sided Correction (AW.OC).
“common neurological disorder expression profile”.431
The numbers of significant DEGs in each of the three432
expression signatures are provided in Table 5.433
The DEGs from the “AD expression profile” in434
the TL brain region were not significantly DE in any435
other disorder included in this study. Hence, the “AD436
expression profile” and the “AD-specific expression437
profile” contained the same 323 genes for the TL438
brain region. The “AD-specific expression profile”439
for all four brain regions is provided in Supplemen-440
tary Table 3.441
The “common neurological disorder expression442
profile” within the four brain regions consisted of443
very little or no DEGs (except for the PL); hence,444
the downstream analysis did not yield any statisti-445
cally significant results of biological relevance. We446
find little robust evidence of shared biology based on447
this data analysis and therefore, exclude all results448
generated from the “common neurological disorder449
expression profile” from this paper; however, we pro-450
vide the complete list of significantly DEGs within451
this profile in Supplementary Table 4.452
Common differentially expressed genes across453
multiple brain regions in AD454
AD is known to affect all brain regions through455
the course of the disease, although not to the same456
degree, similar transcriptomic changes across all457
brain regions were deemed disease-specifi , while458
perturbations in a single brain region were considered459
to be tissue-specific. We were particularly interested460
in disease-specific transcriptomic changes and there-461
fore decided to focus on genes that were found to be462
consistently DE across multiple brain regions.463
Meta-analysis of the AD datasets identified a total464
of 2,495 unique genes as significantly DE. The dis-465
tribution of these genes across the four brain regions466
is shown in Fig. 1. Forty-two genes were found to467
be perturbed across all four brain regions and can be 468
grouped into three sets (Fig. 2) The first group (Gene 469
set 1) are expressed consistently in the same direction 470
across all four brain regions and can be regarded as 471
disease-specific. The second group (Gene set 2) are 472
expressed in the same direction in the TL, FL, and PL, 473
but expression is reversed in the CB brain region, a 474
region suggested to be spared from AD pathology [4, 475
5]. This expression pattern suggests these genes may 476
be involved in AD pathology. Finally, the third group 477
(Gene set 3) are inconsistently expressed across the 478
four brain regions are most likely tissue-specific or 479
even false-positives. 480
From the forty-two genes significantly differen- 481
tially expressed across all brain regions, seven genes 482
were DE in the same direction and belong to the 483
“AD-specific expression profile”, that is, these seven 484
genes (downregulated NDUFS5, SOD1, SPCS1 and 485
upregulated OGT, PURA, RERE, ZFP36L1) were 486
consistently perturbed in all AD brain regions and not 487
in any other brain region of any other disorder used in 488
this study and can be considered unique to AD brains. 489
The expression of these seven genes across AD brains 490
is shown in Fig. 3. 491
Differentially expressed genes in brain regions 492
affected by AD histopathology 493
In AD, the TL, FL, and PL are known to be affected 494
by both plaques and tangles, while the CB brain 495
region is rarely reported to be affected. In addition 496
to identifying genes DE across all brain regions and 497
reversed in the CB brain region, we were also inter- 498
ested in genes perturbed in the TL, FL and PL and 499
not the CB. These genes may also play a role in gen- 500
eral AD histopathology and could be new therapeutic 501
targets in preventing or curing AD. 502
Fifty-five genes were found to be significantly DE 503



















Characteristics of individual non-AD studies included in this meta-analysis
Data ArrayExpress Microarray BeadArray Disorder Sample source (as Mapping to Number of samples after QC
repository Accession
details
Platform stated in the original brain region





Bipolar Disorder Prefrontal Cortex Frontal Lobe 33 (16/17) 34 (25/9)

























Bipolar Disorder Cerebellum Cerebellum 32 (16/16) 46 (29/17)
Schizophrenia Cerebellum Cerebellum 43 (31/12) 46 (29/17)
Bipolar Disorder Parietal Lobe Parietal Lobe 40 (24/16) 45 (32/13)





Huntington’s Disease Frontal Lobe Frontal Lobe 36 (22/14) 27 (19/8)
Huntington’s Disease Cerebellum Cerebellum 38 (22/16) 27 (16/11)
Human Genome
U133B
Huntington’s Disease Cerebellum Cerebellum 38 (23/15) 27 (16/11)










Bipolar Disorder Prefrontal Cortex Frontal Lobe 17 (10/7) 19 (11/8)
Major Depressive Disorder Prefrontal Cortex Frontal Lobe 16 (9/7) 18 (10/8)
Schizophrenia Prefrontal Cortex Frontal Lobe 14 (7/7) 19 (11/8)
Bipolar Disorder Hippocampus Temporal Lobe 18 (11/7) 17 (9/8)
Major Depressive Disorder Hippocampus Temporal Lobe 16 (9/7) 17 (9/8)
Schizophrenia Hippocampus Temporal Lobe 15 (9/6) 18 (10/8)
Nine publicly available non-AD studies were identified and acquired. Separating the studies by tissue resulted in 21 datasets. Each dataset contained both diseased and complimentary healthy
controls. The brain tissue in each of the 21 datasets was mapped to their corresponding cerebral cortex (temporal lobe, frontal lobe, or parietal lobe) or the cerebellum. Due to limited phenotypic
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Table 4
Summary of non-AD study meta-analysis DEGs
Brain region Number of BD Number of Number of HD Number of Number of PD Total number of AW.OC Significant
datasets Schizophrenia datasets MDD datasets datasets datasets DEGs (FDR
datasets adjusted
(case/control) (case/control) (case/control) (case/control) (case/control) (case/control) p≤ 0.05)
Temporal lobe 1 (18/17) 2 (37/37) 0 1 (16/17) 0 4 (71/71) 51
Frontal lobe 3 (80/82) 4 (99/101) 2 (73/56) 1 (16/18) 1 (14/16) 11 (282/273) 149
Parietal lobe 1 (40/45) 1 (51/36) 0 0 0 2 (91/81) 2611
Cerebellum 1 (32/46) 1 (43/46) 2 (76/54) 0 0 4 (151/146) 177
The table illustrates the non-AD dataset and sample distribution across the four brain regions. The case/control numbers represent the total
number of diseased and healthy control subjects within a disease group and brain region. For instance, “3 (80/82)” for BD datasets in the
Frontal lobe region indicates three BD datasets with a combined total of 80 BD and 82 complimentary healthy control subjects. The number of
significant DEGs was identified through a combining p-value method known as Adaptively Weighted with One-sided Correction (AW.OC).
BD, bipolar disease; HD, Huntington’s disease; MDD, major depressive disorder; PD, Parkinson’s disease.
Table 5
Summary of DEGs in each expression signature and brain region
Expression Cerebellum Frontal Parietal Temporal Total
Profile lobe lobe lobe (unique)
AD 867 460 1736 323 2494
Non-AD 177 149 2611 51 2809
AD-specific 828 435 1023 323 1994
Common 39 25 713 0 755
Total (unique) 1005 584 3642 374 –
The “AD” expression profile represents genes identified as DE in the AD vs control meta-analysis.
The “non-AD” expression profile represents genes identified as DE in the non-AD meta-analysis.
The “AD-specific” expression profile is a list of genes DE in AD and no other disorder, and the
“common” expression profile is a list of genes DE in all mental disorder used in this study. Each
expression profile is brain region specific. The “Total (unique)” represents a unique list of the total
number of genes identified as significantly DE across brain regions or expression profiles.
Fig. 1. Overlap of DEGs in the AD expression profile across brain
regions. Forty-two genes were observed to be significantly differ-
entially expressed across all four AD brain regions.
were expressed in the same direction and were not505
DE in the other brain disorders used in this study.506
Ten of these genes (ALDOA, GABBR1, TUBA1A,507
GAPDH, DNM3, KLC1, COX6C, ACTG1, CLTA,508
SLC25A5) were consistently downregulated, and six 509
genes (PRNP, FDFT1, RHOQ, B2M, SPP1, WAC) 510
were consistently upregulated in AD. 511
Furthermore, from the forty-two genes identified as 512
significantly DE across all four AD brain regions, ten 513
genes were in consensus in their expression across 514
the TL, FL, and PL brain region but expression is 515
reversed in the CB. Only 3 of these genes (UBA1, 516
EIF4H, and CLDND1) belong to the “AD-specific 517
expression profile”, and all three genes were signif- 518
icantly downregulated in the TL, FL, and PL, but 519
significantly upregulated in the CB brain region (see 520
Gene set 2 in Fig. 2). 521
Microarray gene expression profiling in 522
RNA-Seq data 523
The 7 genes (NDUFS5, SOD1, SPCS1, OGT, 524
PURA, RERE, ZFP36L1) consistently expressed 525
across all brain regions and the 19 genes (ALDOA, 526
GABBR1, TUBA1A, GAPDH, DNM3, KLC1, 527
COX6C, ACTG1, CLTA, SLC25A5, PRNP, 528
FDFT1, RHOQ, B2M, SPP1, WAC, UBA1, 529
EIF4H, CLDND1) consistently expressed in the TL, 530
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Fig. 2. Expression pattern of genes significantly differentially expressed across all four AD brain regions. The expression values for each
gene was obtained from the meta-summary calculations. Red cells represent downregulated genes, and green cells represent upregulated
genes. Forty-two genes were observed to be significantly perturbed across all four AD brain regions and can be grouped into three “sets”.
Gene set 1 represents genes which are perturbed consistently in the same direction across all AD brain regions and can be considered
disease-specific. Gene set 2 represents genes consistent in expression in the temporal lobe, frontal lobe, and parietal lobe brain regions, but
reversed in the cerebellum brain region; a region often referred to be free from AD pathology. Finally, Gene set 3 represents genes which
are significant DE across all four brain regions, however, directional change is not consistent across the brain regions and may represent
tissue-specific genes or even false positive. The gene names highlighted in red are genes perturbed in AD and not in any other disorder used
in this study and are deemed “AD-specific”.
CB, were queried in the web-based platform Agora532
to compare RNA-Seq based expression profiling.533
The results are provided in Table 6. Agora failed to534
provide expression profiling for 17/26 genes; how-535
ever, from the data available, the genes observed to536
be consistently expressed across all brain regions537
based on microarray data are relatively mirrored in538
RNA-Seq data, specifically genes SPCS1, PURA 539
and ZFP36L1. 540
RNA-Seq data was available for only 6/19 genes 541
(DNM3, COX6C, ACTG1, CLTA, RHOQ, and 542
B2M) expressed in brain regions affected by hall- 543
mark AD pathology (TL, FL, and PL), and were all 544
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Fig. 3. Seven genes consistently significantly differentially expressed in the same direction in all regions of AD brains but not in schizophrenia,
bipolar disorder, Huntington’s disease, major depressive disorder, or Parkinson’s disease brains. These seven genes can be assumed to be
unique to AD brains and may play an important role in disease mechanisms.
brain regions, including the CB, a characteristic unde-546
sired by genes which may be associated with hallmark547
AD pathology.548
“AD Expression Profile” functional gene set549
enrichment and GO analysis550
Gene set enrichment analysis of the “AD expres-551
sion profile” identified 205, 197, 98, and 45552
biological pathways significantly enriched in the553
TL, FL, PL, and CB brain regions, respec-554
tively (Supplementary Table 5). There were ten555
pathways significantly enriched in all four brain556
regions, of which eight are involved in the557
“metabolism of protein” (specifically the transla-558
tion process, the most significant being in CB brain559
region with a q-value = 1.11e-7), one involved in560
“adenosine ribonucleotides de novo biosynthesis”561
(TL q-value = 0.007, FL q-value = 7.56e-5, PL q-562
value = 0.04, CB q-value = 0.03) and one involved563
in the “digestive system” (TL q-value = 0.02, FL q-564
value = 0.02, PL q-value = 0.01, CB p-value = 0.02).565
When excluding the CB brain region, 42 path-566
ways were significantly enriched in the remaining567
three brain regions, of which five pathways568
obtained an FDR adjusted significance p-value of 569
≤0.01. The five pathways are “Alzheimer’s dis- 570
ease” (TL q-value = 6.53e–4, FL q-value = 0.02, 571
PL q-value = 0.01), “Electron Transport Chain” 572
(TL q-value = 0.006, FL q-value = 2.95e–5, PL 573
q-value = 3.69e–5), “Oxidative phosphorylation” 574
(TL q-value = 1.77e–4, FL q-value = 4.99e–8, PL 575
q-value = 4.18e–05), “Parkinson’s disease” (TL 576
q-value = 8.57e–4, FL q-value = 1.59e–6, PL q- 577
value = 1.77e–6), and “Synaptic vesicle cycle” (TL 578
q-value = 5.19e–4, FL q-value = 3.82e–7, PL q- 579
value = 2.03e–4). 580
The biological GO analysis identified 384, 417, 581
216, and 72 biological components as significantly 582
enriched in the TL, FL, PL, and CB brain region 583
respectively (Supplementary Table 6). There were 584
36 pathways significantly enriched across all four 585
brain regions at a p-value threshold of ≤0.05 and 586
nine at an FDR adjusted significant p-value thresh- 587
old of ≤0.01. These nine processes are “cellular 588
component biogenesis” (TL q-value = 1.38e–4, 589
FL q-value = 0.002, PL q-value = 5.86e–4, CB q- 590
value = 0.006), “cellular component organization” 591
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Table 6
Microarray gene expression compared to RNA-Seq gene expression
The 7 genes consistently expressed across all brain regions and the 19 genes consistently expressed in the TL, FL and PL and not/reversed
in the CB were queried in the web-based platform Agora to compare RNA-Seq expression. Only significantly DEGs are shown. Red cells
represent downregulated genes in AD, green cells represent upregulated genes in AD, white cells represent genes not significantly DE, and
grey cells are when data is not available. TL, temporal lobe; FL, frontal lobe; PL, parietal lobe; CB, cerebellum; TCX, temporal cortex; STG,
superior temporal gyrus; PHG, parahippocampal gyrus; IFG, inferior frontal gyrus; FP, frontal pole; DLPFC, dorsolateral prefrontal cortex.
q-value = 3.35e–5, CB q-value = 0.004), “inter-593
species interaction between organisms” (TL594
q-value = 1.13e–41.85e–4, FL q-value = 8.73e–5,595
PL q-value = 5.59e–5, CB q-value = 0.002), “multi-596
organism cellular process” (TL q-value =, FL597
q-value = 4.72e–5, PL q-value = 8.04e–5, CB q-598
value = 0.002), “nervous system development”599
(TL q-value = 1.64e–7, FL q-value = 5.90e–14, PL 600
q-value = 3.82e 8, CB q-value = 0.01), “organon- 601
itrogen compound metabolic process” (TL 602
q-value = 0.002, FL q-value = 1.56e–5, PL q- 603
value = 1.02e–5, CB q-value = 0.002), “symbiosis, 604
encompassing, mutualism through parasitism” 605
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value = 3.18e–4, CB q-value = 0.004), “translational607
initiation” (TL q-value = 0.007, FL q-value = 0.006,608
PL q-value = 2.41e–4, CB q-value = 5.24e–6),609
and “viral process” (TL q-value = 2.82e–4, FL610
q-value = 1.17e–4, PL q-value = 3.18e–4, CB q-611
value = 0.002). Excluding the CB brain region612
resulted in 84 common biological components being613
significantly enriched across the remaining three614
brain regions.615
“AD-specific expression profile” functional gene616
set enrichment and GO analysis617
Analysis of the “AD-specific expression profile”618
identified 205, 196, 40, and 42 pathways as sig-619
nificantly enriched in the TL, FL, PL, and CB620
brain region respectively in the GSEA analysis (Sup-621
plementary Table 7). The analysis identified six622
significantly enriched pathways across all four brain623
regions, and all are involved in “metabolism of pro-624
tein” (specifically the translation process, with the625
most significant pathway being in the PL brain region626
with a q-value = 8.92e–7). The same six pathways627
were identified when the CB region was excluded.628
The GO analysis identified 384, 344, 36, and 72629
significantly enriched biological components for the630
TL, FL, PL, and CB brain region, respectively. Only631
four common biological components were signifi-632
cantly enriched across all four brain regions, and633
all are indicative of interspecies interactions includ-634
ing viral. Excluding the CB identifies only “neural635
nucleus development” (TL q-value = 5.35e–5, FL q-636
value = 0.007, PL q-value = 0.003) as an additional637
component being enriched. The complete biological638
GO analysis results are provided in Supplementary639
Table 8.640
Network analysis hub gene identification641
PPI networks were generated for each expression642
profile and in each of the four brain regions (TL, FL,643
PL, and CB) to identify genes whose protein product644
interacts with other protein products from the same645
expression profile. Genes with more interactions than646
expected are referred to as hub genes and may be of647
biological significance.648
Temporal lobe hub genes649
PPI network analysis was performed on the650
expression profiles of the TL brain region to iden-651
tify key hub genes. The “AD expression profile”652
and the “AD-specific expression profile” both con-653
sisted of the same 323 DEGs which represented654
282 seed proteins with 716 edges (interactions 655
between proteins). Two significant key hub genes 656
were identified; the downregulated Polyubiquitin- 657
C (UBC, p-value = 1.57e–30) and the upregulated 658
Small Ubiquitin-related Modifier 2 (SUMO2, p- 659
value = 3.7e–4). 660
Frontal lobe hub genes 661
The FL “AD expression profile” consisted of 662
460 DEGs which represented 272 seed proteins 663
and 620 edges. Two significant key hub genes 664
were identified; upregulated Amyloid Precursor 665
Protein (APP, p-value = 1.98e–08) and downregu- 666
lated Heat Shock Protein 90-alpha (HSP90AA1, 667
p-value = 0.003). Using the “AD-specific expression 668
profile” identified the same two key hub genes, with 669
APP reaching a significant p-value of 2.11e–09. 670
Parietal lobe hub genes 671
The PL “AD expression profile” consisted of 1,736 672
DEGs which represented 1,437 seed proteins and 673
5,720 edges. Similar to the TL and FL, two significant 674
key hub genes were identified; downregulated Cullin- 675
3 (CUL3, p-value = 1.84e–10) and downregulated 676
UBC (p-value = 1.84e–10). Using the “AD-specific 677
expression profile” (1,023 DEGs, 810 seed proteins, 678
and 2,351 edges) identified UBC as the only key hub 679
gene, with a more significant p-value of 1.84e–10. 680
The CUL3 gene is no longer a significant key hub 681
gene in the network. 682
Cerebellum hub genes 683
The CB “AD expression profile” consisted of 684
867 DEGs which represented 548 seed pro- 685
teins and 1419 edges. Four significant key 686
hub genes were identified: upregulated APP 687
(p-value = 4.24e–26), downregulated Ribosomal Pro- 688
tein 2 (RPS2, p-value = 4.24e–26), downregulated 689
SUMO2 (p-value = 4e–05), and upregulated Glycyl- 690
TRNA Synthetase (GARS, p-value = 0.0207). Using 691
the “AD-specific expression profile” for the same 692
brain region identified APP (p-value = 3.44e–26), 693
RPS2 (p value = 6.61e–06), and SUMO2 (p- 694
value = 3.78e–06) as the key hub genes only. The 695
GARS gene is no longer a key hub gene in the net- 696
work. 697
DISCUSSION 698
In this study, we acquired eighteen publicly avail- 699
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six neurological and mental health disorders; AD,701
BD, HD, MDD, PD, and SCZ. Data was gen-702
erated on seven different expression BeadArrays703
and across two different microarray technologies704
(Affymetrix and Illumina). The eighteen studies con-705
sisted of 3,984 samples extracted from 22 unique706
brain regions which equated to 67 unique datasets707
when separating by disorder and tissue. However,708
due to study and sample outlier analysis, only 43709
datasets (22 AD, 6 BD, 4 HD, 2 MDD, 1 PD,710
and 8 SCZ) totaling 2,667 samples passed QC. We711
grouped the AD datasets by tissue, into the TL, FL,712
PL, and CB brain regions to perform the largest713
microarray AD meta-analysis known to date to our714
knowledge, which identified 323, 460, 1,736, and715
867 significant DEGs, respectively. Furthermore, we716
incorporated transcriptomic information from other717
neurological and mental health disorders to subset718
the initial findings to 323, 435, 1,023, and 828 sig-719
nificant DEGs that were specifically perturbed in the720
TL, FL, PL, and CB brain regions respectively of721
AD subjects.722
Genes specifically perturbed across AD brain723
regions724
Seven genes (downregulated NDUFS5, SOD1,725
SPCS1 and upregulated OGT, PURA, RERE,726
ZFP36L1) were DE in AD brains and not DE in the727
other disorders used in this study. We deemed these728
seven protein-coding genes as “AD-specific”. The729
expression patterns of three genes (SPCS1, PURA,730
and ZFP36L1) were relatively mirrored in RNA-Seq731
data; however, it is important to note the RNA-732
Seq data does not contain expression profiling for733
the PL region, and it also contains three specific734
brain regions within the TL (temporal cortex, supe-735
rior temporal gyrus, and parahippocampal gyrus) and736
FL (Inferior frontal gyrus, frontal pole, and dorso-737
lateral prefrontal cortex). Nevertheless, the SPCS1738
gene was observed to be consistently downregulated739
across all hierarchical AD brain regions available in740
both the microarray and RNA-Seq data. In addition,741
based on a network of genomics and epigenomic742
elements in the region of this genes, i combina-743
tion with phenotypes, the AMP-AD consortia have744
nominated SPCS1 as a druggable target for AD745
treatment.746
Three of the “AD-specific” genes (NDUFS5,747
SOD1, and OGT) have been previously associated748
with AD. Down-regulated NADH Dehydrogenase749
Ubiquinone Fe-S Protein 5 (NDUFS5) gene is750
part of the human mitochondrial respiratory chain 751
complex; a process suggested to be disrupted in 752
AD in multiple studies [41]. A study investigat- 753
ing blood-based AD biomarkers identified 13 genes, 754
including NDUFS5, which was capable of pre- 755
dicting AD with 66% accuracy (67% sensitivity 756
and 75% specificity) in an independent cohort of 757
118 AD and 118 control subjects [42]. The per- 758
turbation in NDUFS5 expression in the blood and 759
brains of AD subjects suggests this gene may have 760
potential as an AD biomarker and warrants further 761
investigation. 762
Downregulated Superoxide Dismutase 1 (SOD1) 763
gene encodes for copper and zinc ion binding proteins 764
which contribute to the destruction of free super- 765
oxide radicals in the body and is also involved in 766
the function of motor neurons [provided by Ref- 767
Seq, Jul 2008]. Mutations in this gene have been 768
heavily implicated as causes of familial amyotrophic 769
lateral sclerosis (ALS) [43] and have also been 770
associated with AD risk [44]. A recent study dis- 771
covered SOD1 deficiency in an amyloid precursor 772
protein-overexpressing mouse model accelerated A 773
oligomerization and also caused tau phosphoryla- 774
tion [45]. They also stated SOD1 isozymes were 775
significantly decreased in human AD patients, and 776
we can now confirm SOD1 is significantly under- 777
expressed at the mRNA level in human AD brains 778
as well. 779
The upregulated O-Linked N-Acetyl Glucosamine 780
Transferase (OGT) gene encodes for a glycosyltrans- 781
ferase that links N-acetylglucosamine to serine and 782
threonine residues (O-GlcNAc). O-GlcNAcylation is 783
the post-translational modification of O-GlcNAc and 784
occurs on both neuronal tau and APP. Increased 785
brain O-GlcNAcylation has been observed to pro- 786
tect against tau and A peptide toxicity [46]. A 787
mouse study has demonstrated a deletion of the 788
encoding OGT gene causes an increase in tau 789
phosphorylation [47]. In this study, we observe a sig- 790
nificant increase in OGT gene expression throughout 791
human AD brains, including the CB where tan- 792
gles are rarely reported, suggesting OGT gene is 793
most likely not solely responsible for the formation 794
of tangles. 795
OGT and O-GlcNAcase (OGA) enzymes facilitate 796
O-GlcNAc cycling, and levels of GlcNAc have also 797
been observed to be increased in the PL of AD brains 798
[48]. Appropriately, OGA inhibitors have been tested 799
for treating AD with promising preliminary results 800
[49], prompting further investigation into targeting 801
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Genes involved in AD histopathology803
The CB brain region is known to be free from804
tau pathology and occasionally free from plaques.805
We exploited the CB brain region as a sec-806
ondary control to identify sixteen genes (ALDOA,807
GABBR1, TUBA1A, GAPDH, DNM3, KLC1,808
COX6C, ACTG1, CLTA, SLC25A5, PRNP,809
FDFT1, RHOQ, B2M, SPP1, WAC) DE specifi-810
cally in TL, FL, and PL and not the CB brain region811
of AD subjects. RNA-Seq data was available for 6812
of these genes (DNM3, COX6C, ACTG1, CLTA,813
RHOQ, and B2M) and all 6 genes failed to repli-814
cate expression patterns observed with microarray815
data. Nevertheless, DNM3 gene has been previously816
associated with AD pathology based on proteomic817
data DNM3 gene encodes a member of a family818
of guanosine triphosphate (GTP)-binding proteins819
that associate with microtubules and are involved820
in vesicular transport. A proteomic study identified821
a module of co-expressed proteins, which included822
DNM3, as negatively correlated with BRAAK stag-823
ing [50]. Although DNM3 gene expression based on824
microarray and RNA-Seq data are in disagreement in825
the CB brain region, a region used in this study to826
aid in determining whether a gene may be involved827
with AD pathology, an independent proteomic study828
demonstrated DNM3 might indeed be association829
with AD pathology. This suggests all 6 genes which830
failed replication in RNA-Seq data may still be831
associated with AD pathology and require further832
confirmation.833
An additional 9 genes (GABBR1, GAPDH,834
PRPN, FDFT1, KLC1, TUBA1A, CLTA, COX6C,835
and SLC25A5), where expression profiling based836
on RNA-Seq data was unavailable, have also been837
previously associated with AD, of which four genes838
(GABBR1, GAPDH, PRPN, and FDFT1) have indi-839
vidually been suggested to be involved with the840
pathogenesis of the disease. GABBR1 gene encodes841
a receptor for gamma-aminobutyric acid (GABA),842
which is the primary inhibitory neurotransmitter in843
the human central nervous system. As observed844
in this study, the GABBR1 gene has been previ-845
ously reported to be downregulated in AD brains846
[16]. GABBR1 receptors are prominent in neuronal847
soma, where neurofibrillary tangle (NFT) forma-848
tion is known to accumulate. A study examined the849
immunohistochemical localization and distribution850
of GABABR1 protein in the hippocampus of AD851
subjects and observed a negative correlation with852
NFT formation and suggested an increase or stable853
expression of GBBR1 could contribute to neuronal 854
resistance to the disease process [51]. 855
GAPDH gene encodes for a member of the 856
glyceraldehyde-3-phosphate dehydrogenase protein 857
family, which catalyzes an essential step in the car- 858
bohydrate metabolism. GAPDH has been shown to 859
interact with APP but not cleaved A, and has 860
been proposed to be directly involved in tau aggrega- 861
tion and NFT formation in AD [52–54]. The PRNP 862
gene encodes for the prion protein, a membrane 863
glycosylphosphatidylinositol-anchored glycoprotein 864
that tends to aggregate into rod-like structures. Muta- 865
tions in the PRNP gene has been associated with 866
AD and prion protein has also been suggested to be 867
involved in the pathogenesis of AD [55]. FDFT1 gene 868
encodes a membrane-associated enzyme located at 869
a branch point in the mevalonate pathway, which 870
generates isoprenoids that have been found to be 871
positively correlated with tau pathology [56]. KLC1 872
gene encodes for Kinesin Light Chain 1 which 873
transports various cargos such as vesicles, mitochon- 874
dria, and the Golgi complex along microtubules. An 875
immunoblotting study observed decrease expression 876
of kinesin light chains (KLCs) in the frontal cor- 877
tex of AD subjects but not in the CB of the same 878
subjects [57]. TUBA1A gene encodes for Tublin 879
Alpha 1a, which has been observed to be perturbed 880
in AD [58], and CLTA gene encodes for clathrin 881
Light Chain A, which has been observed to be per- 882
turbed in AD as well [59]. COX6C and SLC25A5 883
gene encodes for products which interact with mito- 884
chondria and mitochondrial dysfunction in AD has 885
been suggested on numerous occasions [41, 60, 886
61]. 887
We identified an additional three AD-specific 888
genes (UBA1, EIF4H, and CLDND1) which were 889
significant DE in all four brain regions. How- 890
ever, the genes were downregulated in the TL 891
FL and PL but upregulated in the CB brain 892
region. Ubiquitin-Like Modifier Activating Enzyme 893
1 (UBA1) encodes for a protein that catalyzes the 894
first step in ubiquitin conjugation to mark cellu- 895
lar proteins for degradation. Eukaryotic Translation 896
Initiation Factor 4H (EIF4H) encodes for a transla- 897
tion initiation factors, which functions to stimulate 898
the initiation of protein synthesis at the level of 899
mRNA utilization and Claudin Domain Contain- 900
ing 1 (CLDND1) is a transmembrane protein of 901
tight junctions found on endothelial cells [62]. As 902
the CB is the only brain region spared from tangle 903
formation and occasionally from plaque, we sug- 904
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GAPDH, DNM3, KLC1, COX6C, ACTG1, CLTA,906
SLC25A5, PRNP, FDFT1, RHOQ, B2M, SPP1,907
WAC, UBA1, EIF4H, and CLDND1) could poten-908
tially be associated with AD histopathology.909
Translation of proteins perturbed specifically in910
AD brains911
Functional gene set enrichment analysis of the “AD912
expression profile” revealed more pathways were913
significantly perturbed in the TL, followed by the914
FL, PL, and CB, which is the general route AD915
pathology is known to spread through the brain. We916
originally observed ten biological pathways being917
enriched across all AD brain regions, which included918
biological pathways likely to be irrelevant such as the919
“digestive system”. However, when incorporating920
transcriptomic information from non-AD disorders,921
we were able to refine the AD expression signature922
to specific genes perturbed in AD only. This resulted923
in the enrichment of pathways only involved in the924
“metabolism of proteins”, specifically the transla-925
tion process which has been previously suggested in926
be associated with AD on numerous occasions [10,927
11, 14–17]. We now suggest this may be a biological928
process specifically disrupted in AD brains, and not929
BD, HD, MDD, PD, or SCZ brains.930
Previous biological perturbations observed in931
AD are only associated with the temporal lobe932
brain region933
Previous AD studies have consistently suggested934
the immune response [10–13], protein transcrip-935
tion/translation regulation [10, 11, 14–17], calcium936
signaling [10, 18, 19], MAPK signaling [7, 16],937
chemical synapse [7, 18, 19], neurotransmitter [11,938
18, 19], and various metabolism pathways [11, 16,939
17, 20–23] are disrupted in AD. We observe the940
same pathways enriched in our meta-analysis, how-941
ever, only in the TL brain region, a brain region often942
heavily investigated in AD. Except for “metabolism943
of proteins”, we did not observe any of these path-944
ways significantly enriched across all of the four brain945
regions, suggesting these pathways observed to be946
perturbed in previous studies may be tissue-specific947
rather than disease-specific.948
Interspecies interactions possibly involved in AD949
Gene Ontology analysis on the “AD expression950
profile” identified nine different biological compo-951
nents enriched across all four brain regions. However, 952
when we remove genes perturbed in other neurolog- 953
ical or mental health disorders, we only observe four 954
biological components as significantly enriched, and 955
all four were indicative of interspecies interactions. 956
AD brains have a prominent inflammatory compo- 957
nent which is characteristic of infection, and many 958
microbes have been implicated in AD, notably herpes 959
simplex virus type 1 (HSV1), Chlamydia pneumo- 960
nia, and several types of spirochete [63]. A very 961
recent study also identified common viral species in 962
normal and aging brains, with an increased human 963
herpesvirus 6A and human herpesvirus 7 in AD brains 964
[64]. Furthermore, A has been suggested to be an 965
antimicrobial peptide and has been shown to protect 966
against fungal and bacterial infections [65]. Thus, the 967
accumulation of Amay be part of the brains defense 968
mechanism against infections. Although a controver- 969
sial theory, we also observe a viral component in AD 970
brains, and as a result of this meta-analysis, further 971
suggest this maybe AD-specific and warrants further 972
investigation. 973
Network analysis identifies AD-specific APP 974
UBC and SUMO2 hub genes 975
Network analysis identified five (APP, 976
HSP90AA1, UBC, SUMO2, and RPS2) sig- 977
nificant hub genes specific to AD brain regions. 978
APP, UBC, and SUMO2 gene appear as hub genes 979
in multiple brain regions. The APP gene encodes for 980
a cell surface receptor transmembrane APP that is 981
cleaved by secretases to form a number of peptides. 982
Some of these peptides are secreted and can bind 983
to the acetyltransferase complex APBB1/TIP60 984
to promote transcriptional activation, while others 985
form the protein basis of the amyloid plaques in 986
AD brains. In addition, two of the peptides are 987
antimicrobial peptides, having been shown to have 988
bacteriocidal and antifungal activities [provided by 989
RefSeq, Aug 2014]. Changes in APP functions 990
have been suggested to play an essential role in 991
the lack of A clearance, ultimately leading to the 992
formation of plaques [66]. 993
UBC (ubiquitin-C) gene encodes for a 994
Polyubiquitin-C protein which is part of the 995
ubiquitin-proteasome system (UPS), the primary 996
intracellular protein quality control system in 997
eukaryotic cells. UPS has an immense impact on the 998
amyloidogenic pathway of APP processing that 999
generates A [67]. A recent genome-wide associa- 1000
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gene, and through network analysis also identified1002
UBC as a key hub gene. The study validated their1003
findings in a UBC C. elegans model to discover UBC1004
knockout accelerated age-related A toxicity [68].1005
We also observe the UBC gene being downregulated1006
and as a key hub gene in multiple regions of human1007
AD brains, further providing evidence of its key role1008
in AD.1009
Small Ubiquitin-Like Modifier 2 (SUMO2) gene1010
encodes for a protein that binds to target proteins1011
as part of a post-translational modification system, a1012
process referred to as SUMOylation [69]. However,1013
unlike ubiquitin, which targets proteins for degrada-1014
tion, this protein is involved in a variety of cellular1015
processes, such as nuclear transport, transcriptional1016
regulation, apoptosis, and protein stability [provided1017
by RefSeq, Jul 2008]. Early studies have indicated1018
that the SUMO system is likely altered with AD-1019
type pathology, which may impact A levels and tau1020
aggregation [69]. Genetic studies have supported this1021
theory with a genome-wide association study linking1022
SUMO-related genes to late-onset AD [70], with fur-1023
ther studies showing that the two natively unfolded1024
proteins, tau and -synuclein, are sumoylated in vitro1025
[71]. We identified SUMO2 as a significant key1026
hub gene in both the human TL and the CB brain1027
region. However, what makes this discovery inter-1028
esting is that SUMO2 is significantly upregulated1029
in the TL, a region where both plaques and tangles1030
can be observed, but significantly downregulated in1031
the CB, where only plaques have been occasionally1032
observed, but tangles never reported. The upregula-1033
tion of SUMO2 gene may play a vital role in the1034
formation of tangles, and further investigation into1035
this gene is warranted.1036
Limitations1037
Although this study presents novel insights to1038
AD-specific transcriptomic changes in the human1039
brain, limitations to this study must be addressed.1040
Firstly, we meta-analyzed a total of 22 AD and1041
21 non-AD datasets, and many of these datasets1042
lacked necessary experimental processi g or basic1043
phenotypic information such as technical batches,1044
RNA integrity numbers (RIN), age, NFT, clinical1045
gender, or ethnicity, all of which can have con-1046
founding effects. To address this, we incorporated1047
recommended best practices to estimate and cor-1048
rect for both known and hidden batch effects using1049
SVA and COMBAT to ensure data is comparable1050
between experiments and studies. However, this does 1051
not guarantee that all technical variation is completely 1052
removed. 1053
Secondly, the terminology used to label brain tis- 1054
sue varied across studies, with some reporting a broad 1055
region such as the “hippocampus” used in study E- 1056
GEOD-48350, while others were particular to the 1057
tissue layer, such as “hippocampus CA3” in study 1058
E-GEOD-29378. We, therefore, decided to map all 1059
brain tissue as mentioned in each dataset publica- 1060
tion to their hierarchical cerebral cortex lobe (TL, 1061
FL, and PL) and the CB. The mapping procedure 1062
was completed using publicly available literature 1063
defined knowledge, and we assume tissues within 1064
these brain regions are relatively comparable to infer 1065
AD-associated histopathological changes. 1066
Thirdly, this study relied on publicly available tran- 1067
scriptomic data, and as previous research has heavily 1068
investigated brain regions known to be at the fore- 1069
front of disease manifestation, this led to unbalanced 1070
datasets per brain region in both the AD and non-AD 1071
meta-analysis. Subsequently, the AD meta-analysis 1072
consisted of 14, 4, 2, and 2 datasets for the TL, FL, 1073
PL, and CB brain regions respectively, with the PL 1074
brain region consisting of only 74 samples (28 AD 1075
and 46 controls) in total. In addition, the non-AD 1076
meta-analysis lacked expression signatures form all 1077
non-AD diseases across all brain regions (except for 1078
FL). Nevertheless, the brain regions most affected 1079
by each disorder was captured in this study, suggest- 1080
ing we most likely were able to capture key brain 1081
transcriptomic changes relating to each disorder. Fur- 1082
thermore, as AD is known to affect all brain regions, 1083
albeit not to the same extent, we focus on transcrip- 1084
tomic changes observed across all brain regions that 1085
are also not observed in any brain region of the 1086
non-AD subjects, ensuring we capture transcriptomic 1087
signatures unique to AD brains. 1088
Fourthly, the advances in next sequencing tech- 1089
nologies (RNA-Seq) which are capable of profiling 1090
the whole transcriptome, thus not limited by the pre- 1091
defined probes based on known sequencing, would 1092
be ideal for disease discoveries. However, AD and 1093
mental health studies profiled through RNA-Seq is 1094
somewhat limited in the public domain, and those 1095
that have published DE results are based on small 1096
sample numbers, which would fail our selection cri- 1097
teria, such as [72–75]. In addition, these studies lack 1098
the same brain regions and mental health disorders 1099
covered in this meta-analysis. Nevertheless, we were 1100
able to query our genes of interest in the largest known 1101
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contains DE results from over 2100 human brain sam-1103
ples; however, expression profiling was unavailable1104
for 17/26 genes, and DE on the PL was unavailable.1105
Therefore, this study was unable to validate all find-1106
ings in RNA-Seq data.1107
Finally, we assume the non-AD datasets are com-1108
parable through meta-analysis, and by identifying1109
common expression signatures that are not associated1110
with individual disease mechanisms may represent1111
false positives or even a general signature for “brain1112
disorder”. Removing this signature from the AD1113
meta-analysis expression profile may result in tran-1114
scriptomic changes specific to AD brains, revealing1115
more relevant changes to the underlying disease1116
mechanism rather than general diseases. Under this1117
assumption, we observe more relevant and refined1118
biological enrichment results. For example, we orig-1119
inally observed ten biological pathways enriched1120
across all AD brain regions, including biological1121
pathways such as the “digestive system”. However,1122
by refining the AD expression signature by removing1123
genes perturbed in non-AD disorders, only pathways1124
involved in the “metabolism of proteins” remain,1125
which has been previously suggested in be associated1126
with AD on numerous occasions [10, 11, 14–17] This1127
observation provides strong evidence of our assump-1128
tion of incorporating non-AD diseases in this study1129
to infer AD-specific changes as valid.1130
Conclusion1131
We present the most extensive human AD brain1132
microarray transcriptomic meta-analysis study to1133
date, incorporating, brain regions both affected and1134
partially spared by AD pathology, and utilize related1135
non-AD disorders to infer AD-specific brain changes.1136
This led to the identification of seven genes specifi-1137
cally perturbed across all AD brain regions and are1138
considered disease-specific, nineteen genes specifi-1139
cally perturbed in AD brains which could play a role1140
in AD neuropathology, and the refinement of GSEA1141
and GO analysis results to identify specific biologi-1142
cal pathways and components specific to AD. These1143
AD-specific changes may provide new insights into1144
the disease mechanisms, thus making a significant1145
contribution towards understanding the disease.1146
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